21759-69-3Relevant academic research and scientific papers
Synthesis of Spiro-Δ2-Pyrrolin-4-One Pseudo Enantiomers via an Organocatalyzed Sulfa-Michael/Aldol Domino Sequence
Gro?elj, Uro?,Ciber, Luka,Gnidovec, Jan,Testen, ?an,Po?gan, Franc,?tefane, Bogdan,Tav?ar, Ga?per,Svete, Jurij,Ri?ko, Sebastijan
supporting information, p. 5118 - 5126 (2019/11/11)
Δ2-Pyrrolin-4-ones undergo organocatalyzed sulfa-Michael/aldol domino spirocyclizations with mercaptoacetaldehyde dimer. The products contain three contiguous stereocenters (ee up to 99%, dr up to 95:5, 25 examples) and can be transformed into analogues of natural products. With the use of a single catalyst, the absolute configuration of the products were determined by the configuration of the exocyclic double bond of the starting material. These results point at the possibility of a widespread use of unsaturated Δ2-pyrrolin-4-ones in various (organo)catalyzed (cascade) transformations for accessing libraries of 3D-rich pyrrolone-based (spiro)heterocycles. (Figure presented.).
Design of a graphene oxide-SnO2 nanocomposite with superior catalytic efficiency for the synthesis of β-enaminones and β-enaminoesters
Kumar, Aniket,Rout, Lipeeka,Dhaka, Rajendra S.,Samal, Saroj L.,Dash, Priyabrat
, p. 39193 - 39204 (2015/05/20)
A graphene oxide (GO)-SnO2-based nanocomposite was synthesized by decorating the graphene oxide surface with SnO2 nanoparticles via a solvothermal process. The nanocomposite was characterized using Fourier transform infrared spectra (FTIR), FT-Raman spectroscopy, X-ray diffraction (XRD), X-ray photoelectron spectroscopy (XPS), Field-emission Scanning electron microscopy (FE-SEM), Energy dispersive X-ray spectroscopy (EDS), Transmission electron microscopy (TEM) and N2 adsorption/desorption study. The FE-SEM and TEM images demonstrate the uniform distribution of the SnO2 nanoparticles on the GO surface and high-resolution transmission electron microscopy (HRTEM) confirms an average particle size of 8-12 nm. The GO-SnO2 nanocomposite has been found to be an extremely efficient catalyst for the synthesis of β-enaminones and β-enaminoesters in methanol solvent and also, in solventless conditions. The GO-SnO2 nanocomposites exhibited synergistically more superior catalytic efficiency compared to pure graphene oxide and SnO2 nanoparticles. The reaction conditions were optimized by changing different parameters such as catalyst, solvent, catalyst loading, and temperature. It has been found that the catalyst gave higher activity under solventless conditions than methanol. The GO-SnO2 composite was recycled for up to four cycles with minimal loss in activity.
Isoquinolin-1(2H)-ones and 1,6-naphthyridin-5(6H)-ones by an N-acylation-SNAr sequence
Bunce, Richard A.,Nammalwar, Baskar,Gnanasekaran, Krishna Kumar,Cain, Nicholas R.
, p. 838 - 844 (2014/01/23)
A new synthesis of 2,3-dialkyl-4-carbomethoxyisoquinolin-1(2H)-ones and 6,7-dialkyl-8-carbomethoxy-1,6-naphthyridin-5(6H)-ones is reported. The process involves treatment of a β-enaminoester with 2-fluoro-5-nitrobenzoyl chloride, 2-fluorobenzoyl chloride or 2-chloronicotinoyl chloride followed by heating in the presence of base. The conversion, which proceeds by an N-acylation-SNAr reaction sequence, affords 50-86% yields when R 1 is n-alkyl but ≤30% yields when R1 is α-branched.
Bexarotene prodrugs: Targeting through cleavage by NQO1 (DT-diaphorase)
Sch?fer, Anja,Burstein, Ethan S.,Olsson, Roger
supporting information, p. 1944 - 1947 (2014/04/17)
Bexarotene, a retinoid X receptor (RXR) agonist, is being tested as a potential disease modifying treatment for neurodegenerative conditions. To limit the peripheral exposure of bexarotene and release it only in the affected areas of the brain, we designe
LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS
-
Paragraph 0402, (2013/03/26)
Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.
FUNGICIDAL PYRAZOLES
-
Page/Page column 44, (2012/03/26)
Disclosed are compounds of Formula (1) and Formula (1A) including all stereoisomers, N oxides, and salts thereof,wherein Q1, Q2, R1, R2, R4, R5 and X are as defined in the disclosure. Also
POLYCYCLIC LPA1 ANTAGONIST AND USES THEREOF
-
Page/Page column 87, (2012/06/30)
Described herein is the LPA1 antagonist 1- {4'-[3-methyl-4-((R)- l-phenyl-ethoxycarbonylamino)- isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1), or pharmaceutically acceptable salts thereof. Also described are methods of preparing t
Cu(OAc)2/TFA-promoted formal [3 + 3] cycloaddition/oxidation of enamines and enones for synthesis of multisubstituted aromatic amines
Li, Liang,Zhao, Mi-Na,Ren, Zhi-Hui,Li, Jian-Li,Guan, Zheng-Hui
supporting information; experimental part, p. 3506 - 3509 (2012/08/08)
New strategies for the oxidative cycloaddition of enones with enamines are developed. These cycloaddition reactions directly afford substituted aromatic amines, which are important in organic chemistry, in moderate to good yield. Cu(OAc)2/TFA is shown to be essential to achieve high reaction efficiency.
LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS
-
Page/Page column 40, (2012/10/18)
Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in com
POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS
-
Page/Page column 23, (2011/04/24)
Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.
